| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5656363 | HPB | 2017 | 7 Pages |
Abstract
NLR may be a serologic biomarker of early progressive disease after intra-arterial therapy of HCC. Future research should focus on outcomes by treatment type or potentially combining arterial therapies with ablation and/or targeted biologic agents.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Matthew D. Taussig, Mary Ellen Irene Koran, Samdeep K. Mouli, Asma Ahmad, Sunil Geevarghese, Jennifer C. Baker, Andrew J. Lipnik, Fil Banovac, Daniel B. Brown,